China Pharma Holdings, Inc. (NYSE:CPHI – Get Free Report)’s share price was down 1.6% on Tuesday . The company traded as low as $0.5604 and last traded at $0.6148. 296,705 shares changed hands during trading, a decline of 32% from the average daily volume of 439,533 shares. The stock had previously closed at $0.6250.
China Pharma Trading Up 11.8%
The company has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $0.78. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The company has a market cap of $49.84 million, a PE ratio of -2.24 and a beta of 1.14.
Institutional Investors Weigh In On China Pharma
An institutional investor recently raised its stake in China Pharma stock. Citadel Advisors LLC lifted its position in shares of China Pharma Holdings, Inc. (NYSE:CPHI – Free Report) by 31.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 at the end of the most recent reporting period.
China Pharma Company Profile
China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
See Also
- Five stocks we like better than China Pharma
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
